LBCL 2022 - Year in Review

Retrospective analysis found disparities in access to CAR-T therapy in the US, particularly in female patients and patients residing in southern states. Read More ›

The primary analysis of the PILOT study revealed durable overall and complete response rates in patients with LBCL not intended for stem-cell transplantation treated with liso-cel in the 2L setting. Read More ›

Meta-analysis of CAR-T therapy versus high-dose chemotherapy followed by ASCT in 2L R/R LBCL demonstrated superior outcomes with CAR-T without excess toxicity. Read More ›

Retrospective observational study of treatment patterns and real-world outcomes for 2L treatment of patients with relapsed or refractory LBCL demonstrated poor prognosis in those unable to derive benefit from conditioning followed by stem-cell transplantation. Read More ›

Through testing and validation, the novel CAR-T‒specific comorbidity index demonstrated that comorbidities are predictive of mortality after CAR-T therapy. Read More ›

A novel RADscore based on correlation of radiomic features with clinical outcomes in patients with R/R LBCL receiving CAR-T therapy outperformed conventional PET parameters for prognostication. Read More ›

The primary analysis of the TRANSFORM study comparing liso-cel to standard of care in adults with primary refractory or early relapsed LBCL resulted in achievement of key clinical benefit end points. Read More ›